These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 25128961)

  • 21. Long-Term Follow-Up of Normal Tension Glaucoma Patients With TBK1 Gene Mutations in One Large Pedigree.
    Quist TS; Johnson CA; Robin AL; Fingert JH
    Am J Ophthalmol; 2020 Jun; 214():52-62. PubMed ID: 31987900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Visual Field Progression Rates Among the High Tension Glaucoma, Primary Angle Closure Glaucoma, and Normal Tension Glaucoma.
    Ballae Ganeshrao S; Senthil S; Choudhari N; Sri Durgam S; Garudadri CS
    Invest Ophthalmol Vis Sci; 2019 Mar; 60(4):889-900. PubMed ID: 30835290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of visual field progression between relatively low and high intraocular pressure groups in normal tension glaucoma patients.
    Lee J; Kong M; Kim J; Kee C
    J Glaucoma; 2014; 23(8):553-60. PubMed ID: 23751927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study.
    Musch DC; Gillespie BW; Niziol LM; Lichter PR; Varma R;
    Ophthalmology; 2011 Sep; 118(9):1766-73. PubMed ID: 21600658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Ginkgo biloba extract on visual field progression in normal tension glaucoma.
    Lee J; Sohn SW; Kee C
    J Glaucoma; 2013 Dec; 22(9):780-4. PubMed ID: 22595937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline Central Visual Field Defect as a Risk Factor For NTG Progression: A 5-Year Prospective Study.
    Raman P; Suliman NB; Zahari M; Mohamad NF; Kook MS; Ramli N
    J Glaucoma; 2019 Nov; 28(11):952-957. PubMed ID: 31688446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disc haemorrhages in Polish Caucasian patients with normal tension glaucoma.
    Kosior-Jarecka E; Wróbel-Dudzińska D; Łukasik U; Żarnowski T
    Acta Ophthalmol; 2019 Feb; 97(1):68-73. PubMed ID: 30284408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of focal lamina cribrosa defect on glaucomatous visual field progression.
    Faridi OS; Park SC; Kabadi R; Su D; De Moraes CG; Liebmann JM; Ritch R
    Ophthalmology; 2014 Aug; 121(8):1524-30. PubMed ID: 24697910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Visual field progression differences between normal-tension and exfoliative high-tension glaucoma.
    Ahrlich KG; De Moraes CG; Teng CC; Prata TS; Tello C; Ritch R; Liebmann JM
    Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1458-63. PubMed ID: 20042657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between daytime variability of blood pressure or ocular perfusion pressure and glaucomatous visual field progression.
    Lee J; Choi J; Jeong D; Kim S; Kook MS
    Am J Ophthalmol; 2015 Sep; 160(3):522-537.e1. PubMed ID: 26052089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Course and Risk Factors for Visual Field Progression in Normal-Tension Glaucoma With Myopia Without Glaucoma Medications.
    Han JC; Han SH; Park DY; Lee EJ; Kee C
    Am J Ophthalmol; 2020 Jan; 209():77-87. PubMed ID: 31493404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intraocular pressure reduction with topical medications and progression of normal-tension glaucoma: a 12-year mean follow-up study.
    Kim M; Kim DM; Park KH; Kim TW; Jeoung JW; Kim SH
    Acta Ophthalmol; 2013 Jun; 91(4):e270-5. PubMed ID: 23406253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Central visual field progression in normal-tension glaucoma patients with autonomic dysfunction.
    Park HY; Park SH; Park CK
    Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2557-63. PubMed ID: 24692126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the Impact of Uveitis on Visual Field Progression Using Large-Scale Real-World Data.
    Liu X; Kelly SR; Montesano G; Bryan SR; Barry RJ; Keane PA; Denniston AK; Crabb DP
    Am J Ophthalmol; 2019 Nov; 207():144-150. PubMed ID: 31251907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors and long term progression in open angle glaucoma patients.
    Pantalon AD; Feraru C; Chiseliţă D
    Rom J Ophthalmol; 2016; 60(3):174-180. PubMed ID: 29450344
    [No Abstract]   [Full Text] [Related]  

  • 36. Target intraocular pressure for stability of visual field loss progression in normal-tension glaucoma.
    Aoyama A; Ishida K; Sawada A; Yamamoto T
    Jpn J Ophthalmol; 2010 Mar; 54(2):117-23. PubMed ID: 20401559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between intraocular pressure and rate of visual field progression in treated glaucoma.
    Rao HL; Addepalli UK; Jonnadula GB; Kumbar T; Senthil S; Garudadri CS
    J Glaucoma; 2013 Dec; 22(9):719-24. PubMed ID: 22595936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors.
    Musch DC; Gillespie BW; Lichter PR; Niziol LM; Janz NK;
    Ophthalmology; 2009 Feb; 116(2):200-7. PubMed ID: 19019444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Visual Field Outcomes in the Tube Versus Trabeculectomy Study.
    Swaminathan SS; Jammal AA; Kornmann HL; Chen PP; Feuer WJ; Medeiros FA; Gedde SJ;
    Ophthalmology; 2020 Sep; 127(9):1162-1169. PubMed ID: 32327255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Visual and structural prognosis of the untreated fellow eyes of unilateral normal tension glaucoma patients.
    Cho HK; Suh W; Kee C
    Graefes Arch Clin Exp Ophthalmol; 2015 Sep; 253(9):1547-55. PubMed ID: 26126583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.